Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Questcor Pharmaceuticals
Anaheim, California, United States
- Ownership
- Private
- Employees
- ~250
- Development stage
- Other
01
Overview
Questcor’s main product, H.P. Acthar Gel (repository corticotropin injection), was approved and commercialized for multiple indications—including rare, difficult-to-treat autoimmune and inflammatory diseases—prior to the company’s acquisition. Strong revenue growth was driven by dramatic price increases and expanded indications.
- Therapeutic areas
- ImmunologyNeurologyNephrology
- Modalities
- Small moleculePeptideSynthetic glucocorticoid corticosteroid (specifically for repository corticotropin)
- Industry
- Biotech
02
Partnerships
BioVectra (manufacturing partner)Novartis (for Synacthen rights)
Beyond the preview
Go deeper on Questcor Pharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Questcor Pharmaceuticals.